Core Viewpoint - BeiGene (06160) reported a 43.3% increase in Q3 revenue to $3.8 billion, with adjusted net profit of $693 million, exceeding both the firm's and market expectations [2] Financial Performance - Q3 revenue reached $3.8 billion, marking a 43.3% year-over-year increase [2] - Adjusted net profit was $693 million, surpassing expectations [2] Future Guidance - The company raised its revenue guidance for 2025 while slightly lowering cost forecasts [2] - Strong sales outlook for BRUKINSA and improved operational efficiency are expected to drive steady profit and cash flow growth [2] Research and Development - Efficient R&D progress is anticipated to support future product launches, contributing to sustainable long-term growth [2] Investment Rating - The stock maintains a "Buy" rating, with the H-share target price increased from HKD 240 to HKD 252 [2]
大华继显:升百济神州目标价至252港元 维持“买入”评级